Jefferies Upgrades ICU Medical(ICUI.US) to Buy Rating, Raises Target Price to $200
KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Announces Target Price $209
ICU Medical Analyst Ratings
KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating
Needham Maintains ICU Medical(ICUI.US) With Hold Rating
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)
ICU Medical Is Maintained at Overweight by Keybanc
KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Raises Target Price to $198
Jefferies Maintains ICU Medical(ICUI.US) With Hold Rating, Maintains Target Price $183
Jefferies Initiates ICU Medical(ICUI.US) With Hold Rating, Announces Target Price $183
ICU Medical Hold Rating Justified by Limited Growth Prospects and Premium Valuation
ICU Medical Initiated With a Hold at Jefferies
Needham Maintains ICU Medical(ICUI.US) With Hold Rating
ICU Medical Analyst Ratings
Needham Sticks to Its Hold Rating for ICU Medical (ICUI)
Raymond James Maintains ICU Medical(ICUI.US) With Buy Rating, Raises Target Price to $190
ICU Medical Analyst Ratings
ICU Medical Analyst Ratings
ICU Medical (ICUI) Gets a Hold From Needham